SI2516406T1 - Mglu2 agonisti - Google Patents

Mglu2 agonisti

Info

Publication number
SI2516406T1
SI2516406T1 SI201030387T SI201030387T SI2516406T1 SI 2516406 T1 SI2516406 T1 SI 2516406T1 SI 201030387 T SI201030387 T SI 201030387T SI 201030387 T SI201030387 T SI 201030387T SI 2516406 T1 SI2516406 T1 SI 2516406T1
Authority
SI
Slovenia
Prior art keywords
mglu2 agonists
mglu2
agonists
Prior art date
Application number
SI201030387T
Other languages
English (en)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2516406(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2516406T1 publication Critical patent/SI2516406T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201030387T 2009-12-21 2010-12-15 Mglu2 agonisti SI2516406T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists
EP10798419.7A EP2516406B1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
SI2516406T1 true SI2516406T1 (sl) 2013-11-29

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030387T SI2516406T1 (sl) 2009-12-21 2010-12-15 Mglu2 agonisti

Country Status (35)

Country Link
US (1) US8318184B2 (sl)
EP (1) EP2516406B1 (sl)
JP (1) JP5779190B2 (sl)
KR (1) KR101395356B1 (sl)
CN (1) CN102695701B (sl)
AR (1) AR079343A1 (sl)
AU (1) AU2010340039B2 (sl)
BR (1) BR112012017188B1 (sl)
CA (1) CA2784667C (sl)
CR (1) CR20120322A (sl)
CY (1) CY1114880T1 (sl)
DK (1) DK2516406T3 (sl)
DO (1) DOP2012000173A (sl)
EA (1) EA020229B1 (sl)
EC (1) ECSP12011989A (sl)
ES (1) ES2435651T3 (sl)
HK (1) HK1171228A1 (sl)
HN (1) HN2012001160A (sl)
HR (1) HRP20131052T1 (sl)
IL (1) IL220011A (sl)
JO (1) JO2978B1 (sl)
MA (1) MA33824B1 (sl)
MX (1) MX2012007332A (sl)
MY (1) MY160618A (sl)
NZ (1) NZ600305A (sl)
PE (1) PE20121688A1 (sl)
PL (1) PL2516406T3 (sl)
PT (1) PT2516406E (sl)
RS (1) RS53063B (sl)
SG (1) SG181836A1 (sl)
SI (1) SI2516406T1 (sl)
TN (1) TN2012000281A1 (sl)
TW (1) TWI477490B (sl)
UA (1) UA107684C2 (sl)
WO (1) WO2011084437A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733221T3 (es) 2010-02-17 2019-11-28 Takeda Pharmaceuticals Co Compuesto heterocíclico
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
MX2013005623A (es) * 2010-11-18 2013-07-05 Lilly Co Eli Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
US9296710B2 (en) * 2011-06-17 2016-03-29 Eli Lilly And Company Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR102461134B1 (ko) * 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
NZ773901A (en) 2015-04-01 2024-07-26 Akebia Therapeutics Inc Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
EP1517915B1 (en) 2002-06-11 2009-01-21 Eli Lilly And Company Prodrugs of excitatory amino acids
JP4984529B2 (ja) * 2003-06-26 2012-07-25 大正製薬株式会社 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
MX2013005623A (es) * 2010-11-18 2013-07-05 Lilly Co Eli Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.

Also Published As

Publication number Publication date
KR20120094056A (ko) 2012-08-23
CR20120322A (es) 2012-07-10
CA2784667C (en) 2014-11-18
AR079343A1 (es) 2012-01-18
HK1171228A1 (en) 2013-03-22
TWI477490B (zh) 2015-03-21
US8318184B2 (en) 2012-11-27
JP5779190B2 (ja) 2015-09-16
JP2013514974A (ja) 2013-05-02
CA2784667A1 (en) 2011-07-14
HRP20131052T1 (hr) 2013-12-06
JO2978B1 (en) 2016-03-15
CN102695701B (zh) 2014-10-01
AU2010340039B2 (en) 2014-03-20
WO2011084437A1 (en) 2011-07-14
NZ600305A (en) 2014-01-31
DK2516406T3 (da) 2013-10-14
KR101395356B1 (ko) 2014-05-14
BR112012017188B1 (pt) 2021-06-22
IL220011A0 (en) 2012-07-31
BR112012017188A8 (pt) 2016-10-04
ES2435651T3 (es) 2013-12-20
PT2516406E (pt) 2013-10-10
DOP2012000173A (es) 2012-11-30
HN2012001160A (es) 2015-08-24
MX2012007332A (es) 2012-07-20
US20110152334A1 (en) 2011-06-23
MA33824B1 (fr) 2012-12-03
CY1114880T1 (el) 2016-12-14
PE20121688A1 (es) 2012-12-05
EP2516406A1 (en) 2012-10-31
ECSP12011989A (es) 2012-07-31
BR112012017188A2 (pt) 2016-03-22
AU2010340039A1 (en) 2012-08-09
MY160618A (en) 2017-03-15
TW201144290A (en) 2011-12-16
EP2516406B1 (en) 2013-09-18
EA020229B1 (ru) 2014-09-30
IL220011A (en) 2014-03-31
UA107684C2 (xx) 2015-02-10
CN102695701A (zh) 2012-09-26
TN2012000281A1 (en) 2013-12-12
PL2516406T3 (pl) 2014-03-31
EA201290558A1 (ru) 2012-12-28
SG181836A1 (en) 2012-08-30
RS53063B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
GB0919432D0 (en) Use
IL219073A0 (en) Combination
ZA201702958B (en) Novel npr-b agonists
IL220526A0 (en) Kokumi-imparting agent
EP2478768A4 (en) ANTIPHYTOVIRAL AGENT
HK1171228A1 (en) Mglu2 agonists mglu2
IL220527A0 (en) Kokumi-imparting agent
EP2407165A4 (en) ANTIOXIDANTS
EP2488184A4 (en) COMBINATION
GB0922505D0 (en) Use
EP2433502A4 (en) AGENT FOR REMOVING AMERTUME
IL218999A0 (en) Combination
IL218797A0 (en) Combination
EP2501379A4 (en) COMBINATION
IL219000A0 (en) Combination
IL218846A0 (en) Combination
PL2427617T3 (pl) Okucie
IL218801A0 (en) Combination
GB0917304D0 (en) Use
GB0909625D0 (en) Monitors
GB0901585D0 (en) Service Provision
GB0912237D0 (en) Use
GB0907472D0 (en) Use
GB0907963D0 (en) Use
GB0919888D0 (en) Use